The PARTHENON Clinical Development Program

the Role of Ticagrelor in Patients with Atherothrombotic Disease

Paul P Dobesh, Manesh Patel

Research output: Contribution to journalReview article

Abstract

Although the rate of cardiovascular disease (CVD)-related mortality has declined over the last decade, it is still the leading cause of mortality in the USA, accounting for over 1.4 million deaths annually. In addition, total direct (primarily hospital admissions) and indirect costs of CVD in the US is over 316 billion annually and is expected to grow to over 918 billion by 2030. Much of the etiology of CVD is due to atherosclerosis and its thrombotic complications, and central to this is the role of platelets. Atherosclerosis is a systemic disease, with meaningful morbidity and mortality when present in the coronary, cerebral, or major peripheral arteries. The recommended antiplatelet therapy differs based on the vascular bed impacted, with the optimal antiplatelet therapy yet to be defined. The PARTHENON program is a series of completed and ongoing phase III clinical trials investigating the efficacy and safety of ticagrelor in atherosclerotic CVD in comparison with established antiplatelet therapy or placebo. The overall aim of the program is to determine if more potent antiplatelet therapy, with different pharmacology, may reduce cardiovascular events in patients with atherosclerotic disease.

Original languageEnglish (US)
Pages (from-to)433-444
Number of pages12
JournalCardiovascular Drugs and Therapy
Volume31
Issue number4
DOIs
StatePublished - Aug 1 2017

Fingerprint

Cardiovascular Diseases
Mortality
Atherosclerosis
Phase III Clinical Trials
Cost of Illness
Therapeutics
Blood Vessels
Blood Platelets
Arteries
Placebos
Pharmacology
Morbidity
Safety
Ticagrelor

Keywords

  • Acute coronary syndrome
  • Cardiovascular disease
  • Parthenon
  • Ticagrelor

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

The PARTHENON Clinical Development Program : the Role of Ticagrelor in Patients with Atherothrombotic Disease. / Dobesh, Paul P; Patel, Manesh.

In: Cardiovascular Drugs and Therapy, Vol. 31, No. 4, 01.08.2017, p. 433-444.

Research output: Contribution to journalReview article

@article{9b45cf78002c40cbb3f57db0e4029b55,
title = "The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease",
abstract = "Although the rate of cardiovascular disease (CVD)-related mortality has declined over the last decade, it is still the leading cause of mortality in the USA, accounting for over 1.4 million deaths annually. In addition, total direct (primarily hospital admissions) and indirect costs of CVD in the US is over 316 billion annually and is expected to grow to over 918 billion by 2030. Much of the etiology of CVD is due to atherosclerosis and its thrombotic complications, and central to this is the role of platelets. Atherosclerosis is a systemic disease, with meaningful morbidity and mortality when present in the coronary, cerebral, or major peripheral arteries. The recommended antiplatelet therapy differs based on the vascular bed impacted, with the optimal antiplatelet therapy yet to be defined. The PARTHENON program is a series of completed and ongoing phase III clinical trials investigating the efficacy and safety of ticagrelor in atherosclerotic CVD in comparison with established antiplatelet therapy or placebo. The overall aim of the program is to determine if more potent antiplatelet therapy, with different pharmacology, may reduce cardiovascular events in patients with atherosclerotic disease.",
keywords = "Acute coronary syndrome, Cardiovascular disease, Parthenon, Ticagrelor",
author = "Dobesh, {Paul P} and Manesh Patel",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s10557-017-6749-7",
language = "English (US)",
volume = "31",
pages = "433--444",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - The PARTHENON Clinical Development Program

T2 - the Role of Ticagrelor in Patients with Atherothrombotic Disease

AU - Dobesh, Paul P

AU - Patel, Manesh

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Although the rate of cardiovascular disease (CVD)-related mortality has declined over the last decade, it is still the leading cause of mortality in the USA, accounting for over 1.4 million deaths annually. In addition, total direct (primarily hospital admissions) and indirect costs of CVD in the US is over 316 billion annually and is expected to grow to over 918 billion by 2030. Much of the etiology of CVD is due to atherosclerosis and its thrombotic complications, and central to this is the role of platelets. Atherosclerosis is a systemic disease, with meaningful morbidity and mortality when present in the coronary, cerebral, or major peripheral arteries. The recommended antiplatelet therapy differs based on the vascular bed impacted, with the optimal antiplatelet therapy yet to be defined. The PARTHENON program is a series of completed and ongoing phase III clinical trials investigating the efficacy and safety of ticagrelor in atherosclerotic CVD in comparison with established antiplatelet therapy or placebo. The overall aim of the program is to determine if more potent antiplatelet therapy, with different pharmacology, may reduce cardiovascular events in patients with atherosclerotic disease.

AB - Although the rate of cardiovascular disease (CVD)-related mortality has declined over the last decade, it is still the leading cause of mortality in the USA, accounting for over 1.4 million deaths annually. In addition, total direct (primarily hospital admissions) and indirect costs of CVD in the US is over 316 billion annually and is expected to grow to over 918 billion by 2030. Much of the etiology of CVD is due to atherosclerosis and its thrombotic complications, and central to this is the role of platelets. Atherosclerosis is a systemic disease, with meaningful morbidity and mortality when present in the coronary, cerebral, or major peripheral arteries. The recommended antiplatelet therapy differs based on the vascular bed impacted, with the optimal antiplatelet therapy yet to be defined. The PARTHENON program is a series of completed and ongoing phase III clinical trials investigating the efficacy and safety of ticagrelor in atherosclerotic CVD in comparison with established antiplatelet therapy or placebo. The overall aim of the program is to determine if more potent antiplatelet therapy, with different pharmacology, may reduce cardiovascular events in patients with atherosclerotic disease.

KW - Acute coronary syndrome

KW - Cardiovascular disease

KW - Parthenon

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=85028772052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028772052&partnerID=8YFLogxK

U2 - 10.1007/s10557-017-6749-7

DO - 10.1007/s10557-017-6749-7

M3 - Review article

VL - 31

SP - 433

EP - 444

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 4

ER -